Stemline therapeutics inc (STML)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12
Income:
Cost of goods sold

640

3,152

1,071

583

85

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Research and development

11,543

10,546

12,332

10,891

16,953

12,074

11,758

11,184

12,708

16,725

12,417

11,479

9,620

7,284

7,176

6,875

6,532

7,882

7,340

8,199

6,035

5,053

4,979

4,090

7,116

5,608

3,323

4,084

3,161

542

1,221

848

764

Selling, general and administrative

18,541

16,476

15,413

19,002

15,953

14,853

9,647

8,622

5,938

5,213

4,152

4,480

5,367

3,142

3,187

2,860

2,866

2,631

2,234

2,152

1,810

2,037

2,020

2,038

1,988

2,379

2,253

1,071

2,167

772

946

983

389

Total operating expenses

30,725

30,176

28,817

30,477

32,993

26,927

21,405

19,806

18,646

21,938

16,570

15,959

14,988

10,426

10,364

9,736

9,398

10,514

9,575

10,352

7,845

7,091

6,999

6,128

9,105

7,988

5,577

5,155

5,329

1,314

2,167

1,831

1,153

Loss from operations

-21,853

-18,347

-15,484

-17,470

-27,944

-26,927

-21,405

-19,306

-18,646

-21,938

-16,270

-15,660

-14,688

-10,127

-10,065

-9,499

-9,193

-10,308

-9,370

-10,230

-7,724

-6,970

-6,928

-6,057

-9,034

-7,917

-5,577

-5,155

-5,329

-1,314

-2,167

-1,831

-1,153

Other expense, net

-14

-42

-0

0

-4

-11

-0

0

3

-

3

-

-

-

-

-

-

-

-

-

-

-

-

-

7

-

-

-

124

0

0

0

0

Other Income

-

-

-

-

-

-

-

-

-

-

0

-

-

-

1

10

-

-

0

0

0

-

2

0

-

250

0

0

30

24

265

11

0

Interest expense

35

-

-

-

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

11

124

297

82

39

29

28

21

Interest income

643

784

604

610

538

297

361

378

233

192

217

203

122

128

132

140

144

128

137

76

45

30

40

43

42

-

3

3

-

0

2

3

4

Net loss before income taxes

-21,259

-17,641

-14,879

-16,859

-27,410

-

-

-18,928

-

-

-

-

-

-

-9,932

-9,348

-

-10,179

-9,233

-10,153

-7,677

-6,932

-6,885

-6,012

-8,999

-7,666

-5,573

-5,450

-5,505

-1,329

-1,929

-1,844

-1,170

Income tax (expense) benefit

33

-12

8

-18

-3

-

-

-

-

-

-

-

-

-

-8

-26

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-21,293

-17,680

-14,888

-16,841

-27,407

-26,634

-21,043

-18,928

-18,416

-21,749

-16,056

-15,456

-14,566

-10,009

-9,923

-9,322

-9,048

-

-9,233

-10,153

-

-

-

-

-

-

-5,573

-5,450

-5,505

-

-1,929

-1,844

-1,170

Net loss per common share:
Basic and Diluted (in dollars per share)

-0.45

-0.34

-0.34

-0.42

-0.73

-0.91

-0.73

-0.66

-0.69

-0.93

-0.68

-0.66

-0.67

-0.56

-0.56

-0.52

-0.51

-0.58

-0.53

-0.58

-0.46

-0.53

-0.53

-0.47

-0.70

-0.45

-0.45

-0.55

-0.90

-

-0.56

-0.54

-

Weighted-average shares outstanding:
Basic and Diluted (in shares)

47,674

46,971

43,733

40,108

37,550

29,123

29,018

28,567

26,845

23,540

23,464

23,412

21,810

17,886

17,831

17,785

17,716

17,559

17,515

17,497

16,582

12,999

12,950

12,921

12,875

12,813

12,471

9,837

6,147

-

3,441

3,441

-

Basic (in dollars per share)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0.34

Diluted (in dollars per share)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0.34

Basic (in shares)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

3,441

Diluted (in shares)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

3,441

Product revenue, net
Revenue

8,872

11,828

13,332

13,006

5,048

-

-

500

-

0

299

299

299

299

299

236

205

205

205

121

121

121

71

71

71

-

-

-

-

-

-

-

-